KF
VYNT

Krilogy Financial’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Krilogy Financial’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2
Closed -$1K – 788
2016
Q2 		$1K Buy
+2
New +$703 ﹤0.01% 732

Other funds holding VYNT

PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $160M AUM 14.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EGA
Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return

Krilogy Financial's VYNT Position: Q3 2016 in Review

Krilogy Financial sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q3 2016, closing a stake of 2 shares — an estimated $1K sold.

Krilogy Financial first reported a position in VYNT in Q2 2016 and held it in 1 quarter. The position peaked at $1K in Q2 2016. 30 funds tracked by Wall St. Rank hold VYNT as of Q3 2016.

  • Krilogy Financial reported no remaining Vyant Bio, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Krilogy Financial sold 2 Vyant Bio, Inc. Common Stock shares in Q3 2016, an estimated $1K.
  • Krilogy Financial first reported a position in Vyant Bio, Inc. Common Stock in Q2 2016 and held it in 1 quarter.
  • Krilogy Financial's Vyant Bio, Inc. Common Stock position peaked at $1K in Q2 2016.
  • 30 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q3 2016.

Based on Krilogy Financial's 13F filing for Q3 2016, filed 15 Nov 2016.